Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy
Author:
Vellano Christopher P., White Michael G.ORCID, Andrews Miles C.ORCID, Chelvanambi ManojORCID, Witt Russell G., Daniele Joseph R., Titus Mark, McQuade Jennifer L.ORCID, Conforti Fabio, Burton Elizabeth M., Lastrapes Matthew J., Ologun Gabriel, Cogdill Alexandria P.ORCID, Morad GolnazORCID, Prieto Peter, Lazar Alexander J.ORCID, Chu Yanshuo, Han GuangchunORCID, Khan M. A. WadudORCID, Helmink Beth, Davies Michael A.ORCID, Amaria Rodabe N.ORCID, Kovacs Jeffrey J., Woodman Scott E., Patel SapnaORCID, Hwu Patrick, Peoples Michael, Lee Jeffrey E.ORCID, Cooper Zachary A.ORCID, Zhu Haifeng, Gao Guang, Banerjee Hiya, Lau MikeORCID, Gershenwald Jeffrey E.ORCID, Lucci Anthony, Keung Emily Z., Ross Merrick I., Pala Laura, Pagan Eleonora, Segura Rossana Lazcano, Liu Qian, Borthwick Mikayla S.ORCID, Lau Eric, Yates Melinda S.ORCID, Westin Shannon N.ORCID, Wani Khalida, Tetzlaff Michael T., Haydu Lauren E.ORCID, Mahendra Mikhila, Ma XiaoYan, Logothetis ChristopherORCID, Kulstad Zachary, Johnson SarahORCID, Hudgens Courtney W.ORCID, Feng Ningping, Federico Lorenzo, Long Georgina V.ORCID, Futreal P. AndrewORCID, Arur SwathiORCID, Tawbi Hussein A.ORCID, Moran Amy E.ORCID, Wang LinghuaORCID, Heffernan Timothy P.ORCID, Marszalek Joseph R., Wargo Jennifer A.ORCID
Publisher
Springer Science and Business Media LLC
Subject
Multidisciplinary
Reference58 articles.
1. Long, G. V. et al. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. Lancet Oncol. 17, 1743–1754 (2016). 2. Robert, C. et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. New Engl. J. Med. 381, 626–636 (2019). 3. Flaherty, K. T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107–114 (2012). 4. Long, G. V. et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 20, 961–971 (2019). 5. Leung, J. K. & Sadar, M. D. Non-genomic actions of the androgen receptor in prostate cancer. Front. Endocrinol. 8, 2 (2017).
Cited by
67 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|